0001415889-24-014071.txt : 20240522
0001415889-24-014071.hdr.sgml : 20240522
20240522160017
ACCESSION NUMBER: 0001415889-24-014071
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240521
FILED AS OF DATE: 20240522
DATE AS OF CHANGE: 20240522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LILLY ENDOWMENT INC
CENTRAL INDEX KEY: 0000316011
ORGANIZATION NAME:
STATE OF INCORPORATION: IN
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06351
FILM NUMBER: 24973150
BUSINESS ADDRESS:
STREET 1: 2801 NORTH MERIDIAN STREET
CITY: INDIANANAPOLIS
STATE: IN
ZIP: 46208
BUSINESS PHONE: 3179245471
MAIL ADDRESS:
STREET 1: 2801 NORTH MERIDIAN ST
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46208
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ELI LILLY & Co
CENTRAL INDEX KEY: 0000059478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 350470950
STATE OF INCORPORATION: IN
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: LILLY CORPORATE CTR
STREET 2: DROP CODE 1094
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46285
BUSINESS PHONE: 3172762000
MAIL ADDRESS:
STREET 1: LILLY CORPORATE CENTER
STREET 2: DROP CODE 1094
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46285
FORMER COMPANY:
FORMER CONFORMED NAME: LILLY ELI & CO
DATE OF NAME CHANGE: 19941024
4
1
form4-05222024_040506.xml
X0508
4
2024-05-21
0000059478
ELI LILLY & Co
LLY
0000316011
LILLY ENDOWMENT INC
2801 NORTH MERIDIAN STREET
INDIANAPOLIS
IN
46208-0068
false
false
true
false
0
Common Stock
2024-05-21
4
S
0
97907
804.317
D
98800903
D
Common Stock
2024-05-21
4
S
0
39536
805.389
D
98761367
D
Common Stock
2024-05-21
4
S
0
25891
806.432
D
98735476
D
Common Stock
2024-05-21
4
S
0
5145
807.368
D
98730331
D
Common Stock
2024-05-21
4
S
0
6105
808.534
D
98724226
D
Common Stock
2024-05-21
4
S
0
4481
809.449
D
98719745
D
Common Stock
2024-05-21
4
S
0
4680
810.384
D
98715065
D
Common Stock
2024-05-21
4
S
0
1889
812.274
D
98713176
D
Common Stock
2024-05-21
4
S
0
625
812.971
D
98712551
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $804.00 to $804.995, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), and (9) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $805.00 to $805.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $806.00 to $806.99, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $807.00 to $807.97, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $808.01 to $809.005, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $809.01 to $810.00, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $810.01 to $810.98, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.80 to $812.595, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.805 to $813.03, inclusive.
/s/ Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc.
2024-05-22